All News

25 June 2024

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosisAntibodies

25 June 2024

BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into PortfolioMore News

25 June 2024

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy PopulationsDNA RNA and Cells

25 June 2024

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell CarcinomaDNA RNA and Cells

25 June 2024

Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist WithdrawalMore News

25 June 2024

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBEDNA RNA and Cells

25 June 2024

Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck CancerSmall Molecules

24 June 2024

AstriVax enters clinical phase with its novel vaccine platform technologyVaccines

24 June 2024

PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 yearsDNA RNA and Cells

24 June 2024

First gene therapy for prevalent pathologies in neurology receives FDA IND clearance – EG 427 initiating first-in-human clinical studyDNA RNA and Cells

23 June 2024

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association’s 84th Scientific SessionsProteins and Peptides

23 June 2024

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific SessionsProteins and Peptides

23 June 2024

Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia AAntibodies

23 June 2024

NeuroBo Pharmaceuticals’ DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical ModelsProteins and Peptides

23 June 2024

Sun Pharma’s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific SessionsProteins and Peptides

23 June 2024

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune ThrombocytopeniaAntibodies

22 June 2024

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous NivolumabAntibodies

22 June 2024

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2Small Molecules

22 June 2024

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyAntibodies

22 June 2024

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific SessionsDNA RNA and Cells

22 June 2024

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal CancerSmall Molecules

22 June 2024

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)Small Molecules

21 June 2024

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa IndicationDNA RNA and Cells

21 June 2024

Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid TumorsDNA RNA and Cells

21 June 2024

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to RelapseDNA RNA and Cells

21 June 2024

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery PlatformSmall Molecules

21 June 2024

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintideProteins and Peptides

21 June 2024

āshibio Raises $40M in Seed and Series A Financing to Advance Therapies for Bone and Connective Tissue DisordersAntibodies

21 June 2024

HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant LymphomaSmall Molecules

21 June 2024

Kyverna’s KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 TrialDNA RNA and Cells

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

TSLP Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities